[go: up one dir, main page]

BR112013012156A2 - sistema terapêutico transdérmico e método de produção de um sistema terapêutico transdérmico - Google Patents

sistema terapêutico transdérmico e método de produção de um sistema terapêutico transdérmico

Info

Publication number
BR112013012156A2
BR112013012156A2 BR112013012156A BR112013012156A BR112013012156A2 BR 112013012156 A2 BR112013012156 A2 BR 112013012156A2 BR 112013012156 A BR112013012156 A BR 112013012156A BR 112013012156 A BR112013012156 A BR 112013012156A BR 112013012156 A2 BR112013012156 A2 BR 112013012156A2
Authority
BR
Brazil
Prior art keywords
therapeutic system
transdermal therapeutic
producing
transdermal
therapeutic
Prior art date
Application number
BR112013012156A
Other languages
English (en)
Inventor
Fleschhut Jens
Lauer Karin
Feinaeugle Susanne
Original Assignee
Hexal Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43728780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013012156(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hexal Ag filed Critical Hexal Ag
Publication of BR112013012156A2 publication Critical patent/BR112013012156A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112013012156A 2010-11-17 2011-11-17 sistema terapêutico transdérmico e método de produção de um sistema terapêutico transdérmico BR112013012156A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10014713 2010-11-17
PCT/EP2011/005784 WO2012065740A1 (en) 2010-11-17 2011-11-17 Transdermal therapeutic system comprising buprenorphine

Publications (1)

Publication Number Publication Date
BR112013012156A2 true BR112013012156A2 (pt) 2017-12-05

Family

ID=43728780

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013012156A BR112013012156A2 (pt) 2010-11-17 2011-11-17 sistema terapêutico transdérmico e método de produção de um sistema terapêutico transdérmico

Country Status (9)

Country Link
US (2) US9844515B2 (pt)
EP (1) EP2640389B1 (pt)
CN (1) CN103200944B (pt)
AU (1) AU2011331511C1 (pt)
BR (1) BR112013012156A2 (pt)
CA (1) CA2815898C (pt)
DK (1) DK2640389T3 (pt)
ES (1) ES2528650T3 (pt)
WO (1) WO2012065740A1 (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US10010612B2 (en) 2007-05-25 2018-07-03 Indivior Uk Limited Sustained delivery formulations of risperidone compounds
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AU2013305563B2 (en) * 2012-08-24 2018-09-27 Integurx Therapeutics, Llc Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
CN104936582B (zh) 2012-12-21 2018-12-21 帝国制药美国股份有限公司 用于激素和其他药剂的经皮传送的组合物和方法
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11547676B2 (en) 2012-12-28 2023-01-10 Teikoku Seiyaku Co., Ltd. Extended buprenorphine transdermal delivery compositions and methods for using the same
PE20160002A1 (es) * 2013-06-04 2016-01-23 Lohmann Therapie Syst Lts Sistema de liberacion transdermico
CN105579003A (zh) * 2013-07-10 2016-05-11 张洁 利用液体或半固体制剂持续经皮给药的工具及其使用方法
US20150098997A1 (en) 2013-10-07 2015-04-09 Teikoku Pharma Usa, Inc. Methods and Compositions for Treating Attention Deficit Hyperactivity Disorder, Anxiety and Insomnia Using Dexmedetomidine Transdermal Compositions
TWI624278B (zh) * 2013-10-07 2018-05-21 帝國製藥美國股份有限公司 使用非鎮靜性右美托咪啶經皮組成物用於治療戒斷症候群的方法及組成物
CN105764495A (zh) * 2013-10-07 2016-07-13 帝国制药美国公司 用于管理疼痛的包含右旋美托咪啶经皮组合物的方法及组合物
RU2648449C2 (ru) 2013-10-07 2018-03-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Способы и композиции для трансдермальной доставки неседативного количества дексмедетомидина
CN110585173A (zh) 2013-10-07 2019-12-20 帝国制药美国公司 右旋美托咪啶经皮递送装置及其使用方法
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US20160022627A2 (en) * 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
DE102014013448A1 (de) 2014-09-16 2016-03-17 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales Therapeutisches System umfassend Buprenorphin
AR098771A1 (es) * 2014-12-16 2016-06-15 Amarin Tech S A Un dispositivo para la administración transdérmica de rotigotina
US9656441B2 (en) 2015-01-08 2017-05-23 Alfred E. Tiefenbacher ( Gmbh & Co. Kg) Transdermal patch
EP3067050A1 (en) * 2015-03-13 2016-09-14 Acino AG Transdermal therapeutic system with an overtape comprising two adhesive layers
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
EP3349737A4 (en) * 2015-09-14 2019-05-15 Amneal Pharmaceuticals LLC SYSTEM FOR TRANSDERING
AR102214A1 (es) * 2015-10-08 2017-02-15 Amarin Tech S A Un dispositivo para la administración transdermal de buprenorfina
US10835499B2 (en) 2015-12-30 2020-11-17 Corium, Inc. Systems and methods for long term transdermal administration
WO2017172603A1 (en) * 2016-03-28 2017-10-05 Tioga Research, Inc. Topical formulation
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
AU2017281789B2 (en) 2016-06-23 2023-04-13 Corium, LLC. Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
SG11201900692WA (en) 2016-07-27 2019-02-27 Corium Int Inc Donepezil transdermal delivery system
EP3558276B1 (en) 2016-12-20 2024-11-06 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
RU2762896C2 (ru) 2016-12-20 2021-12-23 Лтс Ломанн Терапи-Систем Аг Трансдермальная терапевтическая система, содержащая азенапин
DE102017112543A1 (de) * 2017-06-07 2018-12-13 Amw Gmbh Overtape für ein transdermales Darreichungssystem
CN110799180A (zh) 2017-06-26 2020-02-14 罗曼治疗系统股份公司 含阿塞那平和硅氧烷丙烯酸杂化聚合物的经皮治疗系统
WO2019126531A1 (en) 2017-12-20 2019-06-27 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
KR102255560B1 (ko) 2018-02-20 2021-05-24 주식회사 엘지화학 점착제 조성물 및 이를 포함하는 점착 필름
BR112020017484A2 (pt) * 2018-03-13 2020-12-22 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico para a administração transdérmica de buprenorfina compreendendo um polímero híbrido de acrílico e silicone
BR112020026099A2 (pt) 2018-06-20 2021-03-23 Lts Lohmann Therapie-Systeme Ag sistema terapêutico transdérmico que contém asenapina
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US20210275467A1 (en) * 2018-07-09 2021-09-09 Tyme, Inc Tumor reduction formulations and methods of use thereof
EP3997138A4 (en) * 2019-07-11 2023-02-22 Henkel AG & Co. KGaA ACRYLIC POLYMER AND ADHESIVE COMPOSITIONS
AU2021249031A1 (en) * 2020-03-30 2022-11-10 Shinkei Therapeutics, Inc Transdermal delivery of dextromethorphan
EP3949956A1 (en) * 2020-08-06 2022-02-09 LTS Lohmann Therapie-Systeme AG Esketamine-suspension-tts
JP7173415B2 (ja) * 2020-08-19 2022-11-16 東洋インキＳｃホールディングス株式会社 貼付剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3939376C1 (pt) * 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
DE4301783C1 (de) 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
US5683711A (en) 1993-04-20 1997-11-04 Hexal Pharma Gmbh Active ingredient patch
DE4446600A1 (de) 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US6344211B1 (en) 1994-12-24 2002-02-05 Lts Lohmann Therapie-Systeme Gmbh Transdermal absorption of active substances from subcooled melts
JPH1036265A (ja) 1996-07-19 1998-02-10 Nitto Denko Corp ブプレノルフィン経皮吸収製剤
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
BRPI0507210A (pt) 2004-02-23 2007-06-12 Euro Celtique Sa dispositivo que impede o uso indevido para administração transdérmica de opióide
DE102004020463A1 (de) 2004-04-26 2005-11-10 Grünenthal GmbH Wirkstoffabgabesystem aus einem wirkstoffhaltigen Pflaster und mindestens einem Wirkstoffabgaberegulierungsmittel

Also Published As

Publication number Publication date
CN103200944B (zh) 2016-05-04
US9844515B2 (en) 2017-12-19
CA2815898A1 (en) 2012-05-24
CN103200944A (zh) 2013-07-10
AU2011331511C1 (en) 2018-01-18
AU2011331511A1 (en) 2013-05-30
ES2528650T3 (es) 2015-02-11
EP2640389B1 (en) 2014-12-31
US20180042861A1 (en) 2018-02-15
EP2640389A1 (en) 2013-09-25
DK2640389T3 (en) 2015-03-09
CA2815898C (en) 2018-12-18
US20130331803A1 (en) 2013-12-12
WO2012065740A1 (en) 2012-05-24
AU2011331511B2 (en) 2016-04-07

Similar Documents

Publication Publication Date Title
BR112013012156A2 (pt) sistema terapêutico transdérmico e método de produção de um sistema terapêutico transdérmico
PT2753827E (pt) Sistema de tubagens e método de esvaziamento de um sistema de tubagens
BR112014032458A2 (pt) curativos médicos e método de prender um dispositivo médico
CO7000779A2 (es) Sistema de administración transdermica
BR112013021984A2 (pt) métodos e sistema de tratamento de poço
EP2788083A4 (en) SYSTEM AND METHOD FOR STIMULATION TO RAISE A VOICE LEVEL
DK2602089T3 (da) Resinform til nanotryk og fremgangsmåde til fremstilling deraf
EP2755720A4 (en) SYSTEMS AND METHODS FOR THE THERAPY OF SLEEP APNEA
BR112012024853A2 (pt) método e sistema
BR112013028966A2 (pt) sistema fotobiorreator de calha em v e método de uso
BR112013022764A2 (pt) sistema médico e método
BR112013028133A2 (pt) método e sistema de reconstrução de informações de ativação cardíaca e método de tratamento de um distúrbio de ritmo cardíaco
BR112013018981A2 (pt) sistema e método
BR112013021333A2 (pt) sistema médico e método para um procedimento médico
BR112014013743A2 (pt) sistema e método
EP2777074A4 (en) DRUG SCREENING PROCESSES AND APPLICATIONS THEREOF
PL2601105T3 (pl) Sposób i system przygotowania fiolki
EP2755605A4 (en) SEGMENTARY SPINACH APOPHYSIS ANCHORING SYSTEM AND METHODS OF USE
BR112012030920A2 (pt) método e sistema
EP2720748A4 (en) TRANSDERMAL DRUG DELIVERY SYSTEM AND METHOD OF USE THEREOF
BR112012017067A2 (pt) método e sistema de associação rede-aplicativo
BR112014013600A2 (pt) sistema e método
BR112012033536A2 (pt) sistema de esterilização através de chuveiro e método de utilização
CO6970579A2 (es) Sistema y método para tratar una actividad de excavación
BR112013017063A2 (pt) sistema de áudio e método de operação de um sistema de áudio

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]